Key Adverse Events Following Childhood Cancer

Recruiting
21 years or below
All
Phase N/A
1 Location

Brief description of study

The goal of this study is to identify subjects who are more likely to develop a late-occurring complication(s) after undergoing treatment for childhood cancer.

Detailed description of study

The purpose of this study is to identify key adverse events developing in patients (cases) with a primary cancer diagnosed at age 21 or younger.

Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: childhood cancer
  • Age: 21 years or below
  • Gender: All

Inclusion Criteria
Diagnosis of primary cancer at age 21 or younger
In active follow-up by a Children's Oncology Group (COG) institution
Development of one of the following key adverse events after initiation of prior cancer therapy:Cardiac dysfunction, Myocardial infarction, Ischemic stroke, Avascular necrosis, Subsequent malignant neoplasm
Exclusion Criteria
Prior allogeneic (non-autologous) hematopoietic cell transplant

Updated on 04 Aug 2024. Study ID: 1011003233 (PHO-COG-FALLON-ALTE03N1)

Pre-Screener

Check your eligibility-Test
Take up this questionnaire to help us determine if you have symptoms that are common to this clinical study. If you have the common symptoms, you may be eligible to take part in the study.

Preview complete

The prescreener preview is complete. You may now close the preview.

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team